Riko Kimoto
Riko KIMOTO leads the thematic area of Public Health, which covers AMR, from conceptualisation to implementation at Asia-Europe Foundation (ASEF), an intergovernmental not-for-profit organisation located in Singapore. Prior to joining ASEF, she gained field experience in other continents, including Latin America and Africa. Riko has a Bachelor of Nursing degree from Australian Catholic University, and she is a qualified nurse with several years of clinical experience. She then obtained her Master’s degree in International Public Health (MIPH) from the University of Queensland.
Julian Parkhill
Julian is currently a professor in the Department of Veterinary Medicine at the University of Cambridge. His research interests are focussed on the evolution of bacterial pathogens, and his group uses large-scale genomics to understand their origin and transmission, and how they adapt to selective pressures such as antibiotics and vaccines. Over the last few years his group has identified the global origin and routes of spread of many human and animal pathogens, and discovered mechanisms of resistance to antibiotics and evasion of vaccines. Before moving to Cambridge in 2019, he worked at the Wellcome Sanger Institute for 20 years. He was elected to the Academy of Medical Science in 2009, the American Academy of Microbiology in 2012, and as a Fellow of the Royal Society in 2014.
Fatema Rafiqi
Diana Nasike
David Findlay
Jason Clark
Danjuma Adda
Michael Ferguson
Mike studies the biochemistry of protozoan parasites. With colleagues, he established the Drug Discovery Unit at the University of Dundee in 2006, which has resulted in compounds in Phase 1 and 2 clinical trials and the generation of spin-out companies. Mike is also co-Director of the Dundee Proteomics Facility, one of the largest in Europe, that accelerates discovery and translational science.
Mike believes that research should generate new knowledge and provide returns for its key stakeholders: patients and the taxpayer.
He was a member and Deputy Chair (2012-2021) of the Wellcome board of governors and is on the boards of the Medicines for Malaria Venture (MMV) and UK Biobank.
Leonid Chindelevitch
